Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients

Nephron

Volumn 91, Issue 2, 2002, Pages 222-227

  Nowicki, Michał ^a   Miszczak Kuban, Joanna ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Adrenergic blockers; Fasting; Hemodialysis; Hyperkalemia; Terminal renal failure

Indexed keywords

ALDOSTERONE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; INSULIN; NADOLOL; PLACEBO; POTASSIUM; SODIUM;

ADULT; ALDOSTERONE BLOOD LEVEL; ANURIA; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG SELECTIVITY; FEMALE; HEART RATE; HEMODIALYSIS; HEMODYNAMIC MONITORING; HUMAN; HYPERKALEMIA; INSULIN BLOOD LEVEL; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; GLUCOSE BLOOD LEVEL; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RENOVASCULAR HYPERTENSION; STATISTICAL MODEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ALDOSTERONE; BLOOD GLUCOSE; BLOOD PRESSURE; FASTING; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGE; POTASSIUM; RENAL DIALYSIS; SODIUM; HUMANS; MIDDLE AGED;

EID: 0036016891     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058396     Document Type: Article

References (24)

1. Hyperkalemia: A potential silent killer
2. Variability in potassium removal by hemodialysis
3. Control of serum potassium during fasting in patients with end-stage renal disease
4. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia
5. Adrenergic modulation of potassium metabolism in uremia
6. Extrarenal potassium homeostasis
7. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure
8. + pump in chronic renal failure
9. Hyperkalemia in end-stage renal disease: Mechanisms and management
10. Effect of albuterol treatment on subsequent dialytic potassium removal
11. Prolonged β-adrenergic stimulation: A new way to reduce plasma potassium concentration in hemodialysis patients
12. The use of ACE inhibitors in patients with chronic renal disease - Are there problems?
13. Influence of the renin-angiotensin system stimulation of renal erythropoietin production in patients with various forms of arterial hypertension
14. Carbohydrate metabolism during fasting in hemodialysis patients
15. Potassium regulation during exercise and recovery in humans: Implications for skeletal and cardiac muscle
16. Adrenergic modulation of extrarenal potassium disposal in men with end-stage renal disease
17. Are calcium antagonists proarrythmic
18. Alpha-adrenergic modulation of exercise-induced hyperkalemia in chronic hemodialysis patients
19. Effect of propranolol on some adrenaline-and insulin-induced metabolic changes in man
20. Nadolol in hypertensive patients maintained on long-term hemodialysis
21. Albuterol and insulin for treatment of hyperkalemia in HD patients
22. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: Absence of mediation by insulin or aldosterone
23. Effects of cardioselective (β1) and nonselective (both β1 and β2) adrenergic blockade on serum potassium in patients with chronic renal failure undergoing haemodialysis
24. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery